Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from proliferating cell nuclear antigen

Tumor Biology

Volumn 32, Issue 1, 2011, Pages 63-69

  Xu, Wei ^a   Li, Hui Zhong ^a   Liu, Jun Jie ^a   Guo, Zhen ^a   Zhang, Bao Fu ^a   Chen, Fei Fei ^a   Pei, Dong Sheng ^a   Zheng, Jun Nian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cancer vaccine; Cytotoxic T lymphocyte; Epitope prediction; Ki 67; PCNA

Indexed keywords

CYCLINE; EPITOPE; HLA A ANTIGEN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; KI 67 ANTIGEN; PEPTIDE FRAGMENT;

ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE SEQUENCE; GENETIC ALGORITHM; HUMAN; HUMAN CELL; IMMUNOGENICITY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; BLOOD; BREAST TUMOR; COLORECTAL TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FACTUAL DATABASE; FEMALE; IMMUNOLOGY; STOMACH TUMOR;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A ANTIGENS; HUMANS; KI-67 ANTIGEN; PEPTIDE FRAGMENTS; PROLIFERATING CELL NUCLEAR ANTIGEN; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78751572918     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0098-5     Document Type: Article

References (25)

1. P Van der Bruggen P Chomez, et al. 1991 A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 254 1643 7 10.1126/science.1840703 1840703
2. AW Purcell J McCluskey J Rossjohn 2007 More than one reason to rethink the use of peptides in vaccine design Nat Rev Drug Discov 6 404 14 1:CAS:528:DC%2BD2sXkslyiu7s%3D 10.1038/nrd2224 17473845 (Pubitemid 46696551)
3. SH Van der Burg MS Bijker MJ Welters R Offringa CJ Melief 2006 Improved peptide vaccine strategies,creating synthetic artifical infections to maximize immune efficacy Adv Drug Deliv Rev 127 159 69
4. M Noguchi K Itoh S Suekane A Yao N Suetsugu K Katagiri, et al. 2004 Phase I trial of patient-oriented vaccination in HLA-A*0201-positive patients with metastatic hormonerefractory prostate cancer Cancer Sci 95 77 84 1:CAS:528:DC%2BD2cXhvFOrtb0%3D 10.1111/j.1349-7006.2004.tb03174.x 14720331 (Pubitemid 38208411)
5. M Wobser P Keikavoussi V Kunzmann M Weininger MH Andersen JC Becker 2006 Complete remission of liver metastasis of pancreyatic cancer under vaccination with a HLA-A*0201 restricted peptide derived from the universal tumor antigen survivin Cancer Immunol Immunother 55 1294 8 1:CAS:528: DC%2BD28Xmtl2qtbY%3D 10.1007/s00262-005-0102-x 16315030 (Pubitemid 43992055)
6. C Firbas B Jilma E Tauber 2006 Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects Vaccine 24 4343 53 1:CAS:528:DC%2BD28XksFejsL0%3D 10.1016/j.vaccine.2006.03.009 16581161
7. GA Pietersz DS Pouniotis V Apostolopoalos 2006 Design of peptide-based vaccines for cancer Curr Med Chem 13 1591 607 1:CAS:528:DC%2BD28XlsVGrsL8%3D 10.2174/092986706777441922 16787206 (Pubitemid 43821693)
8. HB Yang PI Hsu SH Chan IC Lee IS Shin NH Chow 1996 Growth kinetics of colorectal adenoma-carcinoma sequence: an immunohistochemical study of proliferation cell nuclear antigen expression Hum Pathol 10 1071 6 10.1016/S0046-8177(96)90286-5 (Pubitemid 26347064)
9. XZ Bai JR Masters N O'Donoghue R Kirby LX Pan M Young, et al. 1999 Prognostic markers in clinically localised prostate cancer Int J Oncol 14 785 91 1:STN:280:DyaK1M7ovFeqtg%3D%3D 10087330
10. BIMAS [ http://www-bimas.cit.nih.gov/molbio/hla-bind/ ]
11. SYFPEITHI [ http://www.syfpeithi.de/Scripts/MHCServer.dll/ EpitopePrediction.htm ], Accessed July 28, 2010.
12. IEDB (ANN)[ http://tools.immuneepitope.org/analyze/html/mhc-binding.html ], Accessed July 28, 2010.
13. HW Nijman JG Houbiers MP Vierboom SH van der Burg JW Drijfhout J D'Amaro, et al. 1993 IdentiWcation of peptide sequences that potentially trigger HLA-A*0201.1-restricted cytotoxic T lymphocytes Eur J Immunol 23 1215 9 1:CAS:528:DyaK3sXkvFeit7o%3D 10.1002/eji.1830230603 7684681 (Pubitemid 23165680)
14. MH Andersen LO Pedersen JC Becker P Straten 2000 Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients Cancer Res 61 869 72
15. P van der Bruggen C Traversari P Chomez C Lurquin E De Plaen B Van den Eynde, et al. 1991 A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 254 1643 7 10.1126/science.1840703 1840703
16. V Brusic VB Bajic N Petrovsky 2004 Computational methods for prediction of T-cell epitopes-a framework for modelling, testing, and applications Methods 34 436 43 1:CAS:528:DC%2BD2cXpslCrtLY%3D 10.1016/j.ymeth.2004.06.006 15542369 (Pubitemid 39469050)
17. AS De Groot L Moise 2007 Prediction of immunogenicity for therapeutic proteins: state of the art Curr Opin Drug Discov Dev 10 332 40
18. Claus Lundegaard, Kasper Lamberth, Mikkel Harndahl, Søren Buus, Ole Lund1and Morten Nielsen. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 2008;36:509-12.
19. JS Lim S Kim HG Lee KY Lee TJ Kown K Kim 1996 Selection of peptides that bind to the HLA-A*0201.1 molecule by molecular modelling Mol Immunol 33 221 30 1:CAS:528:DyaK28XivValsrs%3D 10.1016/0161-5890(95)00065-8 8649443 (Pubitemid 26126288)
20. HH Lin S Ray S Tongchusak EL Reinherz V Brusic 2008 Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research BMC Immunol 9 8 10.1186/1471-2172-9-8 18366636 (Pubitemid 351583869)
21. K Yu N Petrovsky C Schonbach JY Koh V Brusic 2002 Methods for prediction of peptide binding to MHC molecules: a comparative study Mol Med (Camb, Mass) 8 137 48 1:CAS:528:DC%2BD38XmsValsrY%3D
22. B Trost M Bickis A Kusalik 2007 Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools Immunome Res 3 5 10.1186/1745-7580-3-5 17381846 (Pubitemid 46986269)
23. V Apostolopoulos 2009 Peptide-based vaccines for cancer: are we choosing the right peptides? Expert Rev Vaccines 8 259 60 10.1586/14760584.8.3.259 19249965
24. C Buteau SN Markovic E Celis 2002 Challenges in the development of effective peptide vaccines for cancer Mayo Clin Proc 77 339 49 1:CAS:528:DC%2BD38XjtVCmt7s%3D 10.4065/77.4.339 11936929
25. W Shreya Kanodia M Kast 2008 peptide-based vaccines for cancer: realizing their potential Expert Rev Vaccines 7 1533 45 10.1586/14760584.7.10.1533 19053209